Dublin, Aug. 20, 2021 (GLOBE NEWSWIRE) -- The "Global Asthma Drugs Market (2021-2026) by Medication, Administration, Source, Organization, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
The Global Asthma Drugs Market is estimated to be USD 15.6 Bn in 2021 and is expected to reach USD 23.6 Bn by 2026, growing at a CAGR of 8.6%.
The growing incidence of asthma & other breathing syndromes is one of the significant elements increasing the market's progress. Increasing awareness among the population about the accessibility of asthma therapeutics and the growth of blend remedies for the medication of respiratory disorders is another expansion factor for the market.
Some of the other aspects that drive the market are medical sciences development, cumulative healthcare expenditures, widespread research, and upgrades in healthcare structure. Though, stringent government supervisory necessity for the approval of asthma drugs, patent termination of the drugs, and the drugs indicating side effects restrict the market growth.
By medication, the market is classified as quick-relief medications, long-term control medications, and others. Amongst all, the long-term control medications segment is estimated to hold the highest market share during the forecast period.
By Administration, the market is classified as tablets and capsules, liquids, inhalers, injections, and sprays and powders. Amongst all, the tablets and capsules segment is estimated to hold the highest market share during the forecast period.
By Source, the market is classified as environment and generic. Amongst the two, the generic segment is estimated to hold the highest market share during the forecast period.
By Organization, the market is classified as private and public. Amongst the two, the public segment is estimated to hold the highest market share during the forecast period.
By Application, the market is classified as pediatric, adult, and adolescent. Amongst all, the adults segment is estimated to hold the highest market share during the forecast period.
OMRON Healthcare launches a wheeze detection device to pre-empt asthma attacks in kids. - 3rd December 2020
Teva Pharmaceutical Industries Launches Two Digital Inhalers For Asthma Patients. - 22nd September 2020
Some of the companies covered in this report are GlaxoSmithKline, Pfizer, Vectura Group, Boehringer Ingelheim, Roche, Novartis AG, Merck & Co Inc, etc.
Key Topics Covered:
1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.4 Years Considered
1.6 Key Shareholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1.1 Growing Prevalence of Asthma
4.1.2 Increasing Acceptance of Asthma Drugs with Approval from FDA
4.1.3 Government Initiatives Fuels the Awareness of Asthma Drugs
4.2.1 Expiry of Patent Drugs
4.2.2 High Penetration of Generic Drugs
4.3.1 Technological Advancements in the Development of Asthma Drugs
4.3.2 Introduction of Generic Drugs in Developing Regions
4.4.1 Stringent Government Regulations for the Approval of Asthma Drugs
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Asthma Drugs Market, By Medication
6.2 Quick-Relief Medications
6.3 Long-Term Control Medications
7 Global Asthma Drugs Market, By Administration
7.2 Tablets And Capsules
7.6 Sprays And Powders
8 Global Asthma Drugs Market, By Source
9 Global Asthma Drugs Market, By Organization
10 Global Asthma Drugs Market, By Application
11 Global Asthma Drugs Market, By Geography
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
12.3 Strategic Initiatives
13 Company Profiles
AMIKO Digital Health
Chiesi Farmaceutici S.p.A.
Merck & Co Inc
PARI Medical Holding
Roche Holding AG
Teva Pharmaceutical Industries Ltd
For more information about this report visit https://www.researchandmarkets.com/r/p54pfs
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900